| Added by | chplanque |
|---|---|
| Group name | EquipeADV |
| Item Type | Journal Article |
| Title | Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database |
| Creator | Bini et al. |
| Author | Marta Bini |
| Author | Stanislas Quesada |
| Author | Pierre Meeus |
| Author | Manuel Rodrigues |
| Author | Eric Leblanc |
| Author | Anne Floquet |
| Author | Patricia Pautier |
| Author | Frédéric Marchal |
| Author | Magali Provansal |
| Author | Loïc Campion |
| Author | Sylvain Causeret |
| Author | Sophie Gourgou |
| Author | Isabelle Ray-Coquard |
| Author | Jean-Marc Classe |
| Author | Christophe Pomel |
| Author | Thibault De La Motte Rouge |
| Author | Emmanuel Barranger |
| Author | Aude Marie Savoye |
| Author | Cécile Guillemet |
| Author | Laurence Gladieff |
| Author | Martin Demarchi |
| Author | Roman Rouzier |
| Author | C. Courtinard |
| Author | Clémence Romeo |
| Author | Florence Joly |
| Abstract | Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040. ABSTRACT BACKGROUND: In spite of the frequency and clinical impact of BRCA1/2 alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. METHODS: Consecutive patients with BRCA-mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the Unicancer network were extracted from the ESME database. The main objective of the study was the assessment of clinicopathological and treatments parameters. RESULTS: Out of the 8021 patients included in the ESME database, 266 patients matching the selection criteria were included. BRCA1 mutation was found in 191 (71.8%) patients, while 75 (28.2%) had a BRCA2 mutation only; 95.5% of patients received a cytoreductive surgery. All patients received a taxane/platinum-based chemotherapy (median = six cycles). Complete and partial response were obtained in 53.3% and 20.4% of the cases, respectively. Maintenance therapy was administered in 55.3% of the cases, bevacizumab being the most common agent. After a median follow up of 51.7 months, a median progression-free survival of 28.6 months (95% confidence interval (CI) [26.5; 32.7]) and an estimated 5-year median overall survival of 69.2% (95% CI [61.6; 70.3]) were reported. Notably, BRCA1- and BRCA2-mutated cases exhibited a trend towards different median progression-free survivals, with 28.0 (95% CI [24.4; 32.3]) and 33.3 months (95% CI [26.7; 46.1]), respectively (p-value = 0.053). Furthermore, five-year OS for BRCA1-mutated patients was 64.5% (95% CI [59.7; 69.2]), while it was 82.5% (95% CI [76.6; 88.5]) for BRCA2-mutated ones (p-value = 0.029). CONCLUSIONS: This study reports the largest French multicenter cohort of BRCA-mutated HGEOCs based on robust data from the ESME, exhibiting relevant real-world data regarding this specific population. PMID:36011033 | PMC:PMC9406396 | DOI:10.3390/cancers14164040 |
| Publication | Cancers |
| Date | 2022-08-26 00:00:00 |
| Language | en |
| DOI | 10.3390/cancers14164040 |
| URL | https://pubmed.ncbi.nlm.nih.gov/36011033/?utm_source=Firefox&utm_medium=rss&utm_campaign=pubmed-2&utm_content=16WqI68KDOBEDOCNE1P3RxYQYPTwTutpbvUaDhoUuYPuJd459j&fc=20250120064306&ff=20250120064533&v=2.18.0.post9+e462414 |
| Tags | clinic, first |
| Date Added | 2025/01/20 - 14:26:34 |
| Date Modified | 2025/01/20 - 14:59:28 |
| Notes and Attachments | (Attachment) |
Institut de Recherche en Cancérologie de
